Oakbrook Investments LLC lessened its position in shares of Cigna Corp (NYSE:CI) by 12.7% in the second quarter, HoldingsChannel.com reports. The fund owned 17,691 shares of the health services provider’s stock after selling 2,567 shares during the period. Oakbrook Investments LLC’s holdings in Cigna were worth $2,787,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Lowe Wealth Advisors LLC bought a new position in shares of Cigna during the first quarter valued at $34,000. Truvestments Capital LLC bought a new position in shares of Cigna during the first quarter valued at $37,000. Lavaca Capital LLC bought a new position in shares of Cigna during the first quarter valued at $40,000. C J Advisory Inc bought a new position in shares of Cigna during the first quarter valued at $40,000. Finally, Trustcore Financial Services LLC bought a new position in shares of Cigna during the first quarter valued at $49,000. 87.94% of the stock is owned by institutional investors.
CI stock traded up $0.65 during mid-day trading on Friday, hitting $167.20. The company had a trading volume of 90,948 shares, compared to its average volume of 2,075,712. The stock has a market cap of $64.99 billion, a price-to-earnings ratio of 11.76, a PEG ratio of 0.89 and a beta of 0.71. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.70 and a current ratio of 0.70. The firm’s fifty day moving average is $164.28. Cigna Corp has a 12 month low of $141.95 and a 12 month high of $226.60.
Cigna (NYSE:CI) last released its quarterly earnings results on Thursday, May 2nd. The health services provider reported $3.90 EPS for the quarter, topping the Zacks’ consensus estimate of $3.74 by $0.16. Cigna had a net margin of 4.11% and a return on equity of 14.23%. The business had revenue of $33.43 billion during the quarter, compared to analysts’ expectations of $32.79 billion. During the same quarter in the previous year, the company earned $4.11 EPS. The business’s quarterly revenue was up 192.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Cigna Corp will post 16.52 EPS for the current year.
Several equities research analysts have recently weighed in on the stock. Goldman Sachs Group upgraded shares of Puxin from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $51.00 to $56.00 in a research report on Friday, May 3rd. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. Cantor Fitzgerald reiterated a “buy” rating and set a $75.00 price objective on shares of Emergent Biosolutions in a research report on Sunday, April 21st. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $23.00 to $24.00 in a research report on Monday, June 3rd. Finally, UBS Group set a $36.00 price objective on shares of Halliburton and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $217.40.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
See Also: Candlestick
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.